Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2020
gptkb:FDA |
| gptkbp:casnumber |
1394640-06-9
|
| gptkbp:chemical_formula |
C22 H24 N4 O3 S
|
| gptkbp:class |
tyrosine kinase inhibitor
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 |
| gptkbp:contraindication |
hypersensitivity to selpercatinib
|
| gptkbp:developed_by |
gptkb:Loxo_Oncology
|
| gptkbp:dosage_form |
120 mg once daily
|
| gptkbp:formulation |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Selpercatinib
|
| gptkbp:indication |
gptkb:medullary_thyroid_carcinoma
advanced solid tumors RET-altered cancers |
| gptkbp:interacts_with |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| gptkbp:is_monitored_by |
electrolytes
blood pressure liver function tests |
| gptkbp:marketed_as |
brand name Retevmo
|
| gptkbp:mechanism_of_action |
RET inhibitor
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
gptkb:anemia
dizziness fatigue headache nausea hypertension weight loss cough fever vomiting decreased appetite diarrhea rash insomnia constipation dry mouth chills skin rash thrombocytopenia elevated liver enzymes peripheral edema QT prolongation arthralgia dyspnea myalgia |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
RET fusion
RET mutation |
| gptkbp:used_for |
treatment of non-small cell lung cancer
treatment of thyroid cancer |
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:bfsLayer |
6
|